(PharmaNewsWire.Com, July 02, 2019 ) The global medical aesthetics market is projected to reach USD 17.07 billion by 2023 from USD 9.42 billion in 2017, at a CAGR of 10.6% during the forecast period.
The growing adoption of minimally invasive and noninvasive aesthetic procedures, rising adoption among geriatric individuals, increasing public awareness about cosmetic procedures, the availability of technologically advanced & user-friendly products, and the increasing demand for aesthetic treatments among men are the key factors driving the growth of this market.
On the other hand, market growth is limited to a certain extent by factors such as the clinical risks and complications associated with medical aesthetic procedures and the increasing availability and adoption of alternative beauty and cosmetic products.
Product launches, enhancements, and product approvals are the key growth strategies adopted by major players to strengthen their position in the global medical aesthetics market. In addition, strategies such as agreements, partnerships, and collaborations; acquisitions; and expansions were also adopted by several market players to remain competitive in the market.
Top Key Players
Allergan, plc (Ireland), Alma Lasers, Ltd. (Israel), Anika Therapeutics (US), Cutera, Inc. (US), Cynosure (US), El.En. S.p.A. (Italy), Fotona d.o.o. (Slovenia), Nestlé S.A. (Switzerland), Johnson & Johnson (US), Merz Pharma GmbH & Co. KGaA (Germany), Medytox, Inc. (South Korea), Sientra, Inc. (US), Sinclair Pharma PLC (UK), Syneron Medical, Ltd. (US), and Valeant Pharmaceuticals International, Inc. (US) are some of the key players operating in the global medical aesthetics market.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
